See relevant content for battelleventures.com
Investment Type: Venture Capital
Mentions in press and media 10
Date | Title | Description |
18.12.2012 | Proterro Closes $3.5M Financing | Proterro, Inc., an Ewing, NJ-based company making sugar instead of extracting it from crops, closed a $3.5m financing. The round was led by existing investor Braemar Energy Ventures, with participation from new investors Cultivian Ventures ... |
06.08.2012 | Minimally invasive heart surgery device gets follow-on investment from Pa. economic development agency | In addition to Ben Franklin Technology Partners of Northeastern Pennsylvania, other investors have included Life Sciences Greenhouse of Central Pennsylvania, Battelle Ventures and New Hope Ventures. The device is applied to the myocardium b... |
16.07.2012 | Migraine patch application resubmitted for FDA approval | Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA. “With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity ... |
10.05.2012 | Minimally invasive cardiac surgery closure device to cut recovery times | Micro Interventional Devices’ lead device, Permaseal ,uses a sutureless technology to repair the access point of the procedure and closes using a combination of soft tissue anchors and biocompatible elastomers that produce a web structure a... |
15.11.2011 | NuPathe to resubmit migraine patch for approval in 2012 | Migraine headaches affect about 31 million adults in the United States. Symptoms include moderate to severe headache pain, nausea and vomiting, photophobia, or abnormal sensitivity to light, and phonophobia, or abnormal sensitivity to sound... |
18.09.2009 | Friday Q&A: Jane Hollingsworth of NuPathe on Zelrix, migraines and more | Updated 9/18/09 @ 2:42 p.m. Name in title When Jane Hollingsworth takes a pill to help fight a headache, she might get nauseous or sicker still. More than half of American adults suffer similarly, she says, which is a bear of a nuisance for... |
- | NuPathe to resubmit migraine patch for approval in 2012 | NuPathe (NASDAQ: PATH) said it will resubmit a new drug application for its transdermal migraine patch for approval by the U.S. Food and Drug Administration after receiving a complete response letter from the regulator, according to the com... |
- | Minimally invasive heart surgery device gets follow-on investment from Pa. economic development agency | A company with a suture-less closure device for heart surgery procedures intended to reduce blood loss and the amount of time the patient spends on the operating table has received follow-on investment from Ben Franklin Technology Partners ... |
- | Migraine patch application resubmitted for FDA approval | NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration after resolving issues raised in a complete response letter last year. The Zelrix tra... |
- | Minimally invasive cardiac surgery closure device to cut recovery times | As the trend toward minimally invasive cardiac surgery grows, a cardiac medical device startup has developed a sutureless closure device to facilitate transcatheter aortic valve implantation that could cut recovery times and reduce hospital... |